CUE
Price
$1.32
Change
-$0.05 (-3.65%)
Updated
Feb 21 closing price
Capitalization
83.62M
18 days until earnings call
INAB
Price
$0.27
Change
-$0.02 (-6.90%)
Updated
Feb 21 closing price
Capitalization
19.68M
19 days until earnings call
Ad is loading...

CUE vs INAB

Header iconCUE vs INAB Comparison
Open Charts CUE vs INABBanner chart's image
Cue Biopharma
Price$1.32
Change-$0.05 (-3.65%)
Volume$108.72K
Capitalization83.62M
IN8bio
Price$0.27
Change-$0.02 (-6.90%)
Volume$2.17M
Capitalization19.68M
CUE vs INAB Comparison Chart
Loading...
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CUE vs. INAB commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CUE is a Hold and INAB is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (CUE: $1.32 vs. INAB: $0.27)
Brand notoriety: CUE and INAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CUE: 35% vs. INAB: 31%
Market capitalization -- CUE: $83.62M vs. INAB: $19.68M
CUE [@Biotechnology] is valued at $83.62M. INAB’s [@Biotechnology] market capitalization is $19.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CUE’s FA Score shows that 0 FA rating(s) are green whileINAB’s FA Score has 0 green FA rating(s).

  • CUE’s FA Score: 0 green, 5 red.
  • INAB’s FA Score: 0 green, 5 red.
According to our system of comparison, CUE is a better buy in the long-term than INAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CUE’s TA Score shows that 4 TA indicator(s) are bullish while INAB’s TA Score has 4 bullish TA indicator(s).

  • CUE’s TA Score: 4 bullish, 4 bearish.
  • INAB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CUE is a better buy in the short-term than INAB.

Price Growth

CUE (@Biotechnology) experienced а -11.41% price change this week, while INAB (@Biotechnology) price change was -6.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

CUE is expected to report earnings on May 13, 2025.

INAB is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CUE($83.6M) has a higher market cap than INAB($19.7M). CUE YTD gains are higher at: 21.101 vs. INAB (5.560). INAB has higher annual earnings (EBITDA): -28.72M vs. CUE (-40.02M). CUE has more cash in the bank: 32.4M vs. INAB (4M). INAB has less debt than CUE: INAB (5.47M) vs CUE (9.51M). CUE has higher revenues than INAB: CUE (9.53M) vs INAB (0).
CUEINABCUE / INAB
Capitalization83.6M19.7M424%
EBITDA-40.02M-28.72M139%
Gain YTD21.1015.560380%
P/E RatioN/AN/A-
Revenue9.53M0-
Total Cash32.4M4M810%
Total Debt9.51M5.47M174%
FUNDAMENTALS RATINGS
CUE: Fundamental Ratings
CUE
OUTLOOK RATING
1..100
19
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CUEINAB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 12 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IMVT21.270.82
+4.01%
Immunovant
TSBK30.800.46
+1.52%
Timberland Bancorp
RSKD5.35-0.18
-3.25%
Riskified Ltd
CCL23.22-1.34
-5.46%
Carnival Corp
REBN5.15-2.17
-29.64%
Reborn Coffee

CUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, CUE has been loosely correlated with DNLI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CUE
1D Price
Change %
CUE100%
-3.65%
DNLI - CUE
39%
Loosely correlated
-3.98%
VCYT - CUE
36%
Loosely correlated
-4.56%
AXON - CUE
33%
Loosely correlated
-5.28%
AMRN - CUE
32%
Poorly correlated
-0.82%
ARRY - CUE
31%
Poorly correlated
-4.49%
More

INAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INAB has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if INAB jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INAB
1D Price
Change %
INAB100%
-5.07%
IDYA - INAB
47%
Loosely correlated
+0.55%
GRI - INAB
38%
Loosely correlated
-4.64%
SNSE - INAB
32%
Poorly correlated
-5.12%
CUE - INAB
30%
Poorly correlated
-3.65%
SRZN - INAB
28%
Poorly correlated
-3.03%
More